Type 2 diabetes. Type 2 diabetes mellitus
Conditions
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients with Type 2 Diabetes Patients who use glucose lowering oral medications are well controlled by their blood glucose levels.Body mass index 35-25 kg /m 2 will be included in the study.age range from 20-60 years
Exclusion criteria
Exclusion criteria: Use of multi-vitamin and mineral supplements over the past 3 months.Taking corticosteroids and non-steroidal anti-inflammatory drugs.Taking insulin Patients with polycystic ovary syndrome Patients with chronic diseases such as cardiovascular, renal and hepatic disorders, and hypothyroidism and hyperthyroidism Having certain physiological conditions such as pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pentosidine. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of pentosidin via ELISA kit.;Soluble receptor of advanced glycation end products. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of soluble receptor of advanced glycation end products via ELISA kit.;Methylglyoxal. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of methylglyoxal via ELISA kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of the body composition. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Assess body composition using the body composition analyzer.;Physical activity level. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Via IPAQ questionnaire.;Assessment of dietary intake. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: 3-day food record.;Level of fasting blood sugar (FBS). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of fasting blood sugar (FBS) by enzymatic method.;Level of insulin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of insulin by enzymatic method.;Level of hemoglobin A1C. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of hemoglobin A1C by enzymatic method.;HOMA-IR scores. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of HOMA-IR score using formula.;Serum level of total cholesterol (TC). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of total cholesterol (TC) level via enzymatic kit.;Serum level of triglyceride. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of triglyceride (TG) level via enzymatic kit.;Serum level of HDL. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of HDL level via enzymatic kit.;Serum level of LDL. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of LDL using friedewald equation.;Serum level of total antioxidant capacity (TAC). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of total antioxidant capacity (TAC) by spectrophotometry.;Serum level of malondialdehyde (MDA). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of malondialdehyde (MD | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Esmaeili
Tabriz University of Medical Sciences
Outcome results
None listed